iSpecimen Inc. (ISPC) AI Stock Analysis
ISPC AI stock analysis summary
AI ResearchiSpecimen Inc. (ISPC) operates an online marketplace connecting researchers with healthcare provider organizations to procure biospecimens and patient data. The company has experienced significant revenue contraction, with revenue falling 79.2% in FY2025 to $1.9M and trailing twelve-month revenue reaching $466,302. Over the past year, the stock declined 97.2%, closing at $0.92 on October 16, 2026, with a market capitalization of $2.3M.
- Market cap
- $2.3M
- Revenue (TTM)
- $466,302
- P/E
- —
- 1Y return
- -97.2% S&P 500 16.8%
- Avg. target
- $3.00 227.2% vs last close
Bull case
- iSpecimen maintains a net cash position of $4.2M as of June 30, 2026, exceeding its market cap of $2.3M.
- The analyst mean price target of $3.00 sits 227.2% above the last close of $0.92.
- Total debt remains low at $240,903 with a conservative debt-to-equity ratio of 0.14.
Bear case
- Revenue fell 79.2% in FY2025 to $1.9M and decreased a further 78.7% year-over-year in the quarter ended June 30, 2026.
- The company generated negative free cash flow of -$4.2M in FY2025 and has a trailing twelve-month operating margin of -897.1%.
- Share count expanded by 12693.6% over five years, contributing to a 5-year stock return of -100.0%.
What iSpecimen does
Founded in 2009 and based in Lexington, Massachusetts, iSpecimen Inc. facilitates access to human biofluids, tissues, and living cells for life science research. Using its cloud-based iSpecimen Marketplace platform, the company connects medical scientists from biopharmaceutical firms, in vitro diagnostic companies, and academic institutions with healthcare providers, biobanks, blood centers, and laboratories. Researchers use the platform to search for and acquire specific human subjects, biospecimens, and associated clinical data needed for biomedical studies and research discoveries.
Growth and profitability
iSpecimen's annual revenue declined from $11.1M in FY2021 to $1.9M in FY2025, reflecting a 5-year revenue CAGR of -25.1%. In FY2025, revenue fell 79.2% as gross margin dropped to 1.2% from 42.9% in FY2024. Operating margin weakened to -465.4% in FY2025, with a net loss of -$10.5M and an EPS of -$435.30. In the latest quarter ended June 30, 2026, quarterly revenue dropped 78.7% year-over-year. For the trailing twelve months, revenue was $466,302, operating margin was -897.1%, and EPS stood at -$52.98.
Balance sheet and cash flow
As of June 30, 2026, iSpecimen held $4.4M in cash and short-term investments and $240,903 in total debt, resulting in net cash of $4.2M. Shareholders' equity was $1.7M against total assets of $7.4M, with a current ratio of 0.82 and a debt-to-equity ratio of 0.14. Free cash flow was -$4.2M in FY2025, mirroring an operating cash flow of -$4.2M and capital expenditures of $454. Over the five-year period, the company's share count increased by 12693.6%.
Valuation and performance
iSpecimen trades at a price-to-sales multiple of 5.0x, above the 4.1x median of its US-listed Healthcare peers. Its enterprise value of -$1.1M results in an EV/EBITDA of 0.4x, compared to the peer median of 12.0x, and an EV/revenue of 0.2x. Over the past year, ISPC fell 97.2% compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock is down 100.0% versus an 83.0% gain for SPY. At its last close of $0.92 on October 16, 2026, the stock traded 83.1% below its 200-day moving average.
What analysts expect
Analysts have established a mean price target of $3.00, which is 227.2% above the last close of $0.92. Over the last four quarters, iSpecimen reported 1 EPS beat. The company's next earnings date is scheduled for November 16, 2026. Institutional investors hold 2.3% of shares, insiders hold 0.0%, and short interest represents 6.4% of the float.
Key risks and what to watch
- Liquidity pressure is heightened by a current ratio of 0.82 alongside continued negative operating cash flow of -$4.2M in FY2025.
- Operating margins dropped to -897.1% over the trailing twelve months following a gross margin collapse to 1.2% in FY2025.
- The stock displays elevated price volatility with a beta of 1.65 and trades 83.1% below its 200-day average.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ISPC AI stock analysis
This page is an AI-written research summary of iSpecimen Inc. (ISPC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ISPC income statement, ISPC balance sheet, ISPC key metrics, ISPC chart. See the ISPC stock overview for the latest quote and news.
ISPC AI stock analysis FAQ
What was iSpecimen's revenue in FY2025?
iSpecimen reported revenue of $1.9M in FY2025, which was down 79.2% compared to FY2024. Over the trailing twelve months ended June 30, 2026, revenue was $466,302.
How much cash and debt does iSpecimen have?
As of June 30, 2026, iSpecimen had $4.4M in cash and short-term investments and $240,903 in total debt, resulting in net cash of $4.2M.
Does iSpecimen pay a dividend?
iSpecimen does not pay a dividend.
When does iSpecimen report earnings next?
The company's next earnings date is November 16, 2026.